Observational analysis shows high accuracy in breast cancer classification using machine learning models, indicating potential clinical applicability.
This study evaluated machine learning (ML) models on the Wisconsin Breast Cancer Dataset (WBCD), refined to 554 unique instances after addressing 5% missing values via mean imputation, removing 15 duplicates, and normalizing features with Min-Max scaling. Data were split into 80% training and 20% testing, maintaining a 63% benign and 37% malignant distribution. Using 10-fold cross-validation, the random forest, XGBoost, and deep neural network (DNN) models achieved accuracies of 96.5% (95% CI: [93.1-98.6]), 97.4% 95% CI: [94.2-99.1], and 98.0% (95% CI [95.1-99.5]), respectively. The DNN demonstrated a benign precision of 0.97, malignant precision of 1.00, benign recall of 1.00, malignant recall of 0.95, and F1-scores of 0.99 and 0.98, with an ROC-AUC of 0.992 (p < 0.001); its accuracy further improved to 98.9% after Bayesian hyperparameter tuning. Additionally, a convolutional neural network (CNN) using transfer learning (VGG16) achieved 99.3% accuracy, with precision and recall of 99.4% and 99.2%, respectively, although potential domain mismatch issues warrant caution. Optimized DNN and CNN models achieved high accuracy, demonstrating highly reliable diagnostic performance with promising clinical applicability.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: